OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $45.02 +0.01 (+0.01%) As of 07/24/2026 11:07 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$45.02▼$45.0250-Day Range$38.95▼$50.8252-Week Range$35.93▼$83.12Volume210 shsAverage Volume330 shsMarket Capitalization$3.22 billionP/E Ratio3.34Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited. Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access. Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.AI Generated. May Contain Errors. Read More Zealand Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreZLDPF MarketRank™: Zealand Pharma A/S scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingHold Consensus RatingZealand Pharma A/S has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 1 strong buy rating, no buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageZealand Pharma A/S has only been the subject of 4 research reports in the past 90 days.Read more about Zealand Pharma A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-41.35% Earnings GrowthEarnings for Zealand Pharma A/S are expected to decrease by -41.35% in the coming year, from $2.37 to $1.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zealand Pharma A/S is 3.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Zealand Pharma A/S is 3.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.Price to Book Value per Share RatioZealand Pharma A/S has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zealand Pharma A/S's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.82% of the float of Zealand Pharma A/S has been sold short.Short Interest Ratio / Days to CoverZealand Pharma A/S has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Zealand Pharma A/S has recently increased by 46.65%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZealand Pharma A/S does not currently pay a dividend.Dividend GrowthZealand Pharma A/S does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.79 News SentimentZealand Pharma A/S has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zealand Pharma A/S this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsZealand Pharma A/S has minimal institutional ownership at this time.Read more about Zealand Pharma A/S's insider trading history. Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLDPF Stock News HeadlinesZealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590July 24 at 12:51 PM | tipranks.comZealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of "Hold" by AnalystsJuly 15, 2026 | americanbankingnews.comAI billionaires are selling. Quickly.Nvidia CEO Jensen Huang has logged 42 consecutive sell transactions - not a single buy. Peter Thiel liquidated his entire Nvidia position. SoftBank dumped $5.8 billion. And Michael Burry, who famously predicted the housing crash, is now betting against AI stocks. But 40-year investment veteran Alexander Green says the insiders are only half right - and that the biggest AI profits may still be ahead, potentially 10X larger, just not from where most investors are looking.July 26 at 1:00 AM | The Oxford Club (Ad)Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)July 13, 2026 | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (week 27, 2026)July 6, 2026 | markets.businessinsider.comTotal number of shares and voting rights in Zealand Pharma as of June 30, 2026June 30, 2026 | markets.businessinsider.comZealand Pharma major shareholder announcement: The Capital Group Companies, Inc.June 30, 2026 | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (week 26, 2026)June 29, 2026 | markets.businessinsider.comSee More Headlines ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $72.8675 at the start of the year. Since then, ZLDPF stock has decreased by 38.2% and is now trading at $45.02. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its earnings results on Thursday, May, 7th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.50. The firm earned $5.33 million during the quarter, compared to analysts' expectations of $2.81 million. Zealand Pharma A/S had a trailing twelve-month return on equity of 41.80% and a net margin of 68.82%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today7/26/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CIK2068427 Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year Founded1998Profitability EPS (Trailing Twelve Months)$13.48 Trailing P/E Ratio3.34 Forward P/E Ratio19.00 P/E GrowthN/ANet Income$977.29 million Net Margins68.82% Pretax Margin74.39% Return on Equity41.80% Return on Assets38.49% Debt Debt-to-Equity Ratio0.02 Current Ratio37.17 Quick Ratio37.17 Sales & Book Value Annual Sales$1.40 billion Price / Sales2.31 Cash Flow$13.81 per share Price / Cash Flow3.26 Book Value$31.61 per share Price / Book1.42Miscellaneous Outstanding Shares71,530,000Free FloatN/AMarket Cap$3.22 billion OptionableNot Optionable Beta0.88 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:ZLDPF) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...Golden Portfolio | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBlackRock's $2.8B Clue (most investors missed)BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...Awesomely | SponsoredControl 100 shares without spending thousands of dollarsWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
